埃多克萨班在牙科手术中的使用:从EMIT-AF/VTE数据库分析
Cathy Chen1, Manish Saxena2, Christian von Heymann3
1Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.
BDJ open
|August 14, 2023
概括
对于牙科手术,经常建议继续使用edoxaban (一种血液稀释剂). 这项研究发现,当在牙科工作期间管理edoxaban时,血流较低,没有血栓事件,中断主要用于拔牙.
科学领域:
- 心脏病学 心脏病学
- 在口腔外科手术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在牙科手术过程中,抗凝药通常会继续使用.
- 牙医需要有关个体抗凝剂管理的具体数据.
- 在EMIT-AF/VTE计划中,埃多克萨班在心房的患者身上进行了研究.
研究的目的:
- 分析在牙科手术期间的edoxaban中断策略和临床事件.
- 为牙医提供数据管理患者在edoxaban.
主要方法:
- 牙科程序分为清洁或非清洁.
- 观察到埃多克萨班的中断,出血和血栓事件.
- 从程序前5天到程序后29天的后续行动.
主要成果:
- 196名患者接受了350项手术;大多数不是清洁.
- 埃多克萨班在77.9%的清洗中没有中断.
- 拔牙中断是常见的 (67%为一次,53.3%为多次).
- 在1.5%的清洗程序和1.4%的非清洗程序中发生轻微出血.
- 一次严重的出血发生,与清洗程序无关.
- 没有报告发生血栓事件.
结论:
- 埃多克萨班经常保持不间断的牙清洁.
- 在牙抽取方面,程序前的edoxaban中断更频繁.
- 观察到的出血率较低,没有发生血栓事件.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Effects of EDTA on End-Point Detection Methods
304
Different methods, such as visual observance of metal-ion indicators, spectroscopic techniques, and potentiometric methods, can determine the endpoint of an EDTA titration.
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
304
Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563


